CN107474097A - 具有抗肿瘤作用甘草次酸‑肉桂酸衍生物(ga‑ca)的制备方法及其应用 - Google Patents
具有抗肿瘤作用甘草次酸‑肉桂酸衍生物(ga‑ca)的制备方法及其应用 Download PDFInfo
- Publication number
- CN107474097A CN107474097A CN201610395107.XA CN201610395107A CN107474097A CN 107474097 A CN107474097 A CN 107474097A CN 201610395107 A CN201610395107 A CN 201610395107A CN 107474097 A CN107474097 A CN 107474097A
- Authority
- CN
- China
- Prior art keywords
- och
- compound
- preparation
- reaction
- dichloromethane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 title abstract description 20
- 229960003720 enoxolone Drugs 0.000 title abstract description 20
- -1 enoxolone cinnamic acid derivative Chemical class 0.000 title abstract 2
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 39
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 4
- 201000007270 liver cancer Diseases 0.000 claims abstract description 3
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 3
- 230000000118 anti-neoplastic effect Effects 0.000 claims abstract 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 93
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 42
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical group CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 23
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 14
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical group Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical group C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 3
- 238000006482 condensation reaction Methods 0.000 claims description 2
- 238000005984 hydrogenation reaction Methods 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 claims 1
- 238000011160 research Methods 0.000 abstract description 5
- 230000003013 cytotoxicity Effects 0.000 abstract description 4
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 208000019065 cervical carcinoma Diseases 0.000 abstract 1
- 229910052697 platinum Inorganic materials 0.000 abstract 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 52
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 39
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 30
- 239000000243 solution Substances 0.000 description 27
- 238000003756 stirring Methods 0.000 description 22
- 239000000843 powder Substances 0.000 description 17
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical group C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 229940041181 antineoplastic drug Drugs 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000001816 cooling Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- MPDGHEJMBKOTSU-WFJWTYAKSA-N (2s,4as,6as,6br,10s,12as)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid Chemical compound C12C(=O)C=C3C4C[C@@](C)(C(O)=O)CC[C@]4(C)CC[C@@]3(C)[C@]1(C)CCC1[C@]2(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-WFJWTYAKSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 3
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229930016911 cinnamic acid Natural products 0.000 description 3
- 235000013985 cinnamic acid Nutrition 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 150000002611 lead compounds Chemical class 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000007908 nanoemulsion Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000007939 sustained release tablet Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- AFDXODALSZRGIH-QPJJXVBHSA-N (E)-3-(4-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC=C(\C=C\C(O)=O)C=C1 AFDXODALSZRGIH-QPJJXVBHSA-N 0.000 description 1
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 1
- VEEPGIBHWRABJA-UHFFFAOYSA-N 1-benzyl-3,5-dimethylpyrazol-4-amine Chemical compound CC1=C(N)C(C)=NN1CC1=CC=CC=C1 VEEPGIBHWRABJA-UHFFFAOYSA-N 0.000 description 1
- JPQWWJZORKTMIZ-ZZXKWVIFSA-N 2,5-Dimethoxycinnamic acid Chemical compound COC1=CC=C(OC)C(\C=C\C(O)=O)=C1 JPQWWJZORKTMIZ-ZZXKWVIFSA-N 0.000 description 1
- FEGVSPGUHMGGBO-UHFFFAOYSA-N 2-methoxy cinnamic acid Natural products COC1=CC=CC=C1C=CC(O)=O FEGVSPGUHMGGBO-UHFFFAOYSA-N 0.000 description 1
- YTFVRYKNXDADBI-SNAWJCMRSA-N 3,4,5-trimethoxycinnamic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1OC YTFVRYKNXDADBI-SNAWJCMRSA-N 0.000 description 1
- QAXPUWGAGVERSJ-UHFFFAOYSA-N 3-(2,3-dimethoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC=CC(C=CC(O)=O)=C1OC QAXPUWGAGVERSJ-UHFFFAOYSA-N 0.000 description 1
- LZPNXAULYJPXEH-AATRIKPKSA-N 3-Methoxycinnamic acid Chemical compound COC1=CC=CC(\C=C\C(O)=O)=C1 LZPNXAULYJPXEH-AATRIKPKSA-N 0.000 description 1
- RURHILYUWQEGOS-VOTSOKGWSA-N 4-Methylcinnamic acid Chemical compound CC1=CC=C(\C=C\C(O)=O)C=C1 RURHILYUWQEGOS-VOTSOKGWSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- YTFVRYKNXDADBI-UHFFFAOYSA-N O-Methylsinapic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1OC YTFVRYKNXDADBI-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- ZYOPDNLIHHFGEC-FNORWQNLSA-N Trans-2, 3, 4-Trimethoxycinnamate Chemical compound COC1=CC=C(\C=C\C(O)=O)C(OC)=C1OC ZYOPDNLIHHFGEC-FNORWQNLSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000007805 chemical reaction reactant Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- AFDXODALSZRGIH-UHFFFAOYSA-N p-coumaric acid methyl ether Natural products COC1=CC=C(C=CC(O)=O)C=C1 AFDXODALSZRGIH-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明提供了一类新型具有抗肿瘤作用甘草次酸‑肉桂酸衍生物的制备方法和在制备抗肿瘤药物中的应用,其结构符合通式1或2。本发明中化合物对宫颈癌、肝癌、结肠癌细胞系具有选择性抑制作用,与顺铂相比,对正常细胞毒性较小,具有良好的研究前景。
Description
技术领域
本发明涉及一种具有抗肿瘤活性的甘草次酸-肉桂酸衍生物及其制备方法和应用,属于药物化学领域。
背景技术
目前,肿瘤疾病是世界上危害人类生命健康的杀手之一,目前临床上治疗肿瘤疾病的药物大多在杀死肿瘤细胞的同时,也很大程度上杀伤正常机体组织,因此,如何发现高效低毒、选择性抗肿瘤药物是当前国际药物研发的热点和难点。借鉴药物设计的结构拼合原理,从中医经典方药中发现“祛邪不伤正”先导化合物的研究思路,引起越来越多学者的关注。当前大量研究表明“桂枝甘草汤”方中活性成分甘草次酸(GA)、肉桂酸及其类似物(CA)可以作为抗癌先导化合物发现的母体结构加以修饰。甘草次酸(GA)是国际上细胞毒领域研究的明星分子,同时肉桂酸及其类似物(CA)具有选择性的抗癌作用。
本发明以具有抗肿瘤甘草次酸(GA)与肉桂酸衍生物(CA)为起始原料,进行化学拼合合成本发明化合物。对该类化合物的活性评价主要围绕抗肿瘤(尤其宫颈癌癌)方面展开,分别测试了类似物对3种癌症细胞系(Hela、HepG-2、HT-29)及正常细胞系(MDCK、HY926、H9C2)的细胞毒活性。
发明内容
本发明以中药复方配伍理论和化学药物结构拼合原理为指导,运用化学合成方法,筛选出一类结构骨架新颖,活性明确的甘草次酸-肉桂酸衍生物(命名为GA-CA),对于研究和开发结构明确的先导化合物具有重大的研究意义。
本发明的目的之一是提供一种具有结构通式1的化合物。
本发明的目的之二是提供一种具有结构通式2的化合物。
本发明的目的之三是提供通式化合物1、2的制备方法。
本发明的目的之四是提供通式化合物1、2在制备抗肿瘤药物中的应用。
本发明的目的之五是提供一种具有抗肿瘤作用的药物组合物。
本发明的目的是通过如下技术方案实现的:
具有抗肿瘤作用的式1化合物,
其中,
R1、R2、R4选自-H、-OCH3中的一种;
R3选自-H、-OCH3、-CH3中的一种;
具有抗肿瘤作用的式2化合物,
其中,R1、R2、R3、R4选自-H、-OCH3中的一种;
进一步,本发明化合物编号及结构式见表1、表2:
表1
表2
本发明甘草次酸-肉桂酸衍生物的合成路线如下:
上述反应中R代表-H、-CH3或-OCH3中的任意一种;
试剂和条件:(i)CH2Cl2,DMAP/EDCI,24h;(ii)THF,Pd/C,H2,2h.
其中,所述反应在二氯甲烷、乙酸乙酯、甲醇或它们各种比例的混合溶剂中进行;涉及缩合反应在20-40℃下进行,催化剂为4-二甲氨基呲啶(DMAP),缩合剂为1-乙基-3-(3-二甲胺丙基)碳二亚胺盐酸盐(EDCI)或1,3-二环己基碳二亚胺(DCC);所述氢化反应在四氢呋喃(THF)中进行;涉及催化剂为钯碳(Pd/C),反应在-20℃至50℃进行。
进一步,上述制备方法中,相应的原料与肉桂酸衍生物的摩尔比为1∶2;相应的原料与缩合剂的摩尔比为1∶1.2~1∶1.5;相应的原料与催化剂的摩尔比为1∶0.2~1∶0.5。
本发明还提供式1、2化合物在制备抗肿瘤药物中的应用。进一步,所述肿瘤为宫颈癌、肝癌、结肠癌细胞系。
本发明化合物具有明显抑制肿瘤细胞系(Hela、HepG-2、HT-29)生长的活性,但正常细胞系(MDCK、HY926、H9C2)细胞毒性较小。其中,化合物8a的抗肿瘤活性近于阳性药顺铂,且对非癌细胞毒性较小。
实验例 MTT法观察本发明组合物GA-CA对癌细胞及正常细胞的增殖影响
1.仪器与材料
Thermo 3111型CO2培养箱;HFsafe生物安全柜;Multiskan GO酶标仪;京立牌LD5-2B型台式低速离心机;Olympus IX71倒置荧光显微镜改良型RPMI-1640培养基、胎牛血清、0.25%胰蛋白酶溶液、噻唑蓝、磷酸盐缓冲液(赛默飞世尔生物化学制品北京有限公司);Amresco二甲基亚砜(DMSO);
人宫颈癌细胞系Hela;人肝癌细胞系HepG-2;人结肠癌细胞系HT-29;犬肾上皮细胞MDCK;血管内皮细胞HY926;心肌细胞H9C2;
实验药物:本发明化合物1a-9a、1b-4b;反应原料甘草次酸(GA);阳性药物注射用顺铂(301001CF;齐鲁制药有限公司)。
2.方法
2.1不同细胞株的培养
Hela、HepG-2、HT-29、MDCK、HY926、H9C2细胞培养在含10%胎牛血清的1640/DMEM培养液中,放置于37℃、5%的CO2培养箱中温育。细胞均呈贴壁状态生长,在倒置显微镜下观察生长状况,待细胞数量适量时传代培养。
2.2初筛细胞抑制率
取对数生长期的Hela、HepG-2、HT-29、MDCK、HY926、H9C2细胞,以3×103/孔的数量接种于96孔培养板中,在含5%CO2的湿化培养箱中37℃培养24h。每孔分别加入100μL待测化合物,使每孔浓度分别为20μM和40μM。设置细胞对照组及空白对照组,药物组每浓度重复3孔,细胞对照组和空白对照组重复3孔。培养箱中继续培养72h后,每孔加20μL MTT孵育4h,弃去上清,再加100μL DMSO,振荡10min,酶标仪490nm波长测得吸光度值并记录结果,抑制率/%=[1-(A给药-A空白)/(A正常-A空白)]×100%。将40μM浓度下,抑制率大于50%的化合物进行复筛并计算IC50值。
2.3复筛细胞抑制率
操作方法如2.2项,取对数生长期的Hela、HepG-2、HT-29、MDCK、HY926、H9C2细胞,以3×103/孔的数量接种于96孔培养板中,在含5%CO2的湿化培养箱中37℃培养24h;每孔分别加入100μL待测化合物,使最终浓度分别为100、50、25、12.5、6.25、3.125μM。设置细胞对照组及空白对照组,药物组每浓度重复3孔,细胞对照组和空白对照组重复3孔。培养箱中继续培养72h后,每孔加20μL MTT孵育4h,弃去上清,再加100μL DMSO,振荡10min,酶标仪490nm波长测得吸光度值,记录结果,并计算化合物的IC50值,细胞抑制率(%)=[1-(A给药-A空白)/(A正常-A空白)]×100%。
3.结果
3.1本发明化合物1a-9a、1b-4b和反应原料GA对3种肿瘤细胞系(Hela、HepG-2、HT-29)和3种正常细胞(MDCK、HY926、H9C2)的IC50值如表3所示。
表3不同药物对不同肿瘤细胞株和正常细胞株的IC50值
4.结论
本发明化合物表现出抑制肿瘤细胞系(Hela、HepG-2、HT-29)增殖的活性,且对正常细胞系(MDCK、HY926、H9C2)表现出较低的细胞毒性。其中,化合物8a对各种癌细胞均表现出较好的抑制增殖的作用,尤其是Hela(IC50=8.54μM),与顺铂相比(IC50<10μM),8a对正常细胞的毒性较小。表明该类化合物可用于抗肿瘤药物的研究。
具体实施方式
实施例1
Cinnamoyl-3β-Hydroxy-11-oxoolean-12-en-30-oic acid(1a)
将6.0mmol桂皮酸、0.6mmolDMAP置于100ml圆底烧瓶,加入50ml二氯甲烷后,搅拌10-20min,待充分溶解后加入3.0mmol甘草次酸,搅拌10min,冰浴至4℃,缓慢滴加EDCI的二氯甲烷溶液,滴加完毕继续保持4℃约30min后,室温反应24h。反应完毕后,依次用饱和碳酸氢钠溶液、饱和食盐水各洗两遍,无水硫酸钠干燥,回收溶剂,所得固体上柱层析(二氯甲烷∶甲醇=200∶1)分离,得到白色粉末0.810g,产率为45.0%。
1H-NMR(500MHz,CDCl3)(ppm):0.85,0.93,0.97,1.15,1.20,1.24,1.39(s,each,3H,7×-CH3),4.67(m,1H),5.73(s,1H,=CH-),6.45(d,J=16.0Hz,1H,-CH=),7.35-7.40(m,3H,Ar-H),7.53-7.54(m,2H,Ar-H),7.67(d,J=16.0Hz,1H,-CH=),1.00-3.00(22H,methyl-and methylene-of triterpenoid structure).13C-NMR(125MHz,CDCl3)(ppm):16.6,17.0,17.5,18.8,23.5,23.8,26.6,26.6,28.3,28.6,28.7,31.1,32.0,32.9,37.1,37.9,38.5,39.0,41.0,43.4,43.9,45.6,48.4,55.2,61.9,80.8,119.0,128.2,128.6,129.0,130.3,134.7,144.5,167.0,169.6,181.6(-COOH),200.5(-C=O).MS(ESI)m/z:599[M-H]-,calcd.for C39H52O5600.
实施例2
(4-Methyl)cinnamoyl-3β-Hydroxy-11-oxoolean-12-en-30-oic acid(2a)
将6.0mmol 4-甲基桂皮酸、0.6mmolDMAP置于100ml圆底烧瓶,加入50ml二氯甲烷后,搅拌10-20min,待充分溶解后加入3.0mmol甘草次酸,搅拌10min,冰浴至4℃,缓慢滴加EDCI的二氯甲烷溶液,滴加完毕继续保持4℃约30min后,室温反应24h。反应完毕后,依次用饱和碳酸氢钠溶液、饱和食盐水各洗两遍,无水硫酸钠干燥,回收溶剂,所得固体上柱层析(二氯甲烷∶甲醇=200∶1)分离,得到白色粉末0.872g,产率为47.3%。
1H-NMR(500MHz,CDCl3)(ppm):0.84,0.92,0.96,1.14,1.19,1.23,1.38(s,each,3H,7×-CH3),2.37(s,3H,-CH3),4.66(m,1H),5.72(s,1H,=CH-),6.40(d,J=16.0Hz,1H,-CH=),7.18(d,J=8.0Hz,2H,Ar-H),7.43(d,J=8.0Hz,2H,Ar-H),7.64(d,J=16.0Hz,1H,-CH=),1.00-3.00(22H,methyl-and methylene-of triterpenoid structure).13C-NMR(125MHz,CDCl3)(ppm):16.6,17.0,17.5,18.8,21.6,23.5,23.8,26.5,26.6,28.2,28.6,28.7,31.0,32.0,32.9,37.1,37.9,38.4,38.9,41.0,43.4,43.9,45.6,48.4,55.2,61.9,80.7,117.8,128.2,128.6,129.7,131.9,140.7,144.5,167.2,169.6,181.7(-COOH),200.5(-C=O).MS(ESI)m/z:613[M-H]-,calcd.for C40H54O5614.
实施例3
(2-methoxy)cinnamoyl-3β-Hydroxy-11-oxoolean-12-en-30-oic acid(3a)
将6.0mmol 2-甲氧基桂皮酸、0.6mmolDMAP置于100ml圆底烧瓶,加入50ml二氯甲烷后,搅拌10-20min,待充分溶解后加入3.0mmol甘草次酸,搅拌10min,冰浴至4℃,缓慢滴加EDCI的二氯甲烷溶液,滴加完毕继续保持4℃约30min后,室温反应24h。反应完毕后,依次用饱和碳酸氢钠溶液、饱和食盐水各洗两遍,无水硫酸钠干燥,回收溶剂,所得固体上柱层析(二氯甲烷∶甲醇=200∶1)分离,得到白色粉末0.863g,产率为45.7%。
1H-NMR(500MHz,CDCl3)(ppm):0.84,0.92,0.96,1.14,1.19,1.23,1.38(s,each,3H,7×-CH3),3.88(s,3H,-OCH3),4.66(m,1H),5.72(s,1H,=CH-),6.52(d,J=16.0Hz,1H,-CH=),6.91(d,J=8.0Hz,1H,Ar-H),6.95(t,J=7.5Hz,1H,Ar-H),7.35(m,1H,Ar-H),7.51(m,1H,Ar-H),7.98(d,J=16.0Hz,1H,-CH=),1.00-3.00(22H,methyl-and methylene-oftriterpenoid structure).13C-NMR(125MHz,CDCl3)(ppm):16.6,17.0,17.5,18.8,23.5,23.8,26.5,26.6,28.2,28.6,28.7,31.0,32.0,32.8,37.1,37.8,38.4,38.9,40.9,43.3,43.9,45.6,48.4,55.1,55.6(-OCH3),61.8,80.5,111.2,119.4,120.8,123.6,128.5,129.0,131.5,139.9,158.4,167.5,169.7,181.7(-COOH),200.6(-C=O).MS(ESI)m/z:629[M-H]-,calcd.for C40H54O6630.
实施例4
(3-methoxy)cinnamoyl-3β-Hydroxy-11-oxoolean-12-en-30-oic acid(4a)
将6.0mmol 3-甲氧基桂皮酸、0.6mmolDMAP置于100ml圆底烧瓶,加入50ml二氯甲烷后,搅拌10-20min,待充分溶解后加入3.0mmol甘草次酸,搅拌10min,冰浴至4℃,缓慢滴加EDCI的二氯甲烷溶液,滴加完毕继续保持4℃约30min后,室温反应24h。反应完毕后,依次用饱和碳酸氢钠溶液、饱和食盐水各洗两遍,无水硫酸钠干燥,回收溶剂,所得固体上柱层析(二氯甲烷∶甲醇=200∶1)分离,得到白色粉末1.238g,产率为65.5%。
1H-NMR(400MHz,CDCl3)(ppm):0.84,0.93,0.97,1.15,1.20,1.24,1.39(s,each,3H,7×-CH3),3.84(s,3H,-OCH3),4.67(m,1H),5.72(s,1H,=CH-),6.43(d,J=16.0Hz,1H,-CH=),6.93(dd,J=8.0,2.0Hz,1H,Ar-H),7.05(s,1H,Ar-H),7.13(d,J=8.0Hz,1H,Ar-H),7.28-7.32(m,1H,Ar-H),7.63(d,J=16.0Hz,1H,-CH=),1.00-3.00(22H,methyl-andmethylene-of triterpenoid structure).13C-NMR(100MHz,CDCl3)(ppm):16.6,17.0,17.6,18.9,23.5,23.9,26.6,26.7,28.3,28.6,28.7,31.1,32.0,32.9,37.2,37.9,38.5,39.0,41.1,43.4,44.0,45.6,48.4,55.2,55.5(-OCH3),61.9,80.9,113.0,116.3,119.3,120.9,128.7,130.0,136.1,144.4,160.1,166.9,169.5,181.4(-COOH),200.4(-C=O).MS(ESI)m/z:629[M-H]-,calcd.for C40H54O6630.
实施例5
(4-methoxy)cinnamoyl-3β-Hydroxy-11-oxoolean-12-en-30-oic acid(5a)
将6.0mmol 4-甲氧基桂皮酸、0.6mmolDMAP置于100ml圆底烧瓶,加入50ml二氯甲烷后,搅拌10-20min,待充分溶解后加入3.0mmol甘草次酸,搅拌10min,冰浴至4℃,缓慢滴加EDCI的二氯甲烷溶液,滴加完毕继续保持4℃约30min后,室温反应24h。反应完毕后,依次用饱和碳酸氢钠溶液、饱和食盐水各洗两遍,无水硫酸钠干燥,回收溶剂,所得固体上柱层析(二氯甲烷∶甲醇=200∶1)分离,得到白色粉末0.935g,产率为49.4%。
1H-NMR(500MHz,CDCl3)(ppm):0.84,0.92,0.95,1.14,1.19,1.23,1.38(s,each,3H,7×-CH3),3.83(s,3H,-OCH3),4.65(m,1H),5.72(s,1H,=CH-),6.32(d,J=16.0Hz,1H,-CH=),6.90(d,J=8.5Hz,2H,Ar-H),7.48(d,J=8.5Hz,2H,Ar-H),7.62(d,J=16.0Hz,1H,-CH=),1.00-3.00(22H,methyl-and methylene-of triterpenoid structure).13C-NMR(125MHz,CDCl3)(ppm):16.6,17.0,17.5,18.8,23.5,23.8,26.5,26.6,28.2,28.6,28.7,31.0,32.0,32.8,37.1,37.8,38.4,38.9,41.0,43.3,43.9,45.6,48.4,55.2,55.6(-OCH3),61.8,80.5,114.4,116.4,127.4,128.6,129.8,144.1,161.4,167.3,170.0,181.6(-COOH),200.6(-C=O).MS(ESI)m/z:631[M+H]+,calcd.for C40H54O6630.
实施例6
(2,3-dimethoxy)cinnamoyl-3β-Hydroxy-11-oxoolean-12-en-30-oic acid(6a)
将6.0mmol 2,3-二甲氧基桂皮酸、0.6mmolDMAP置于100ml圆底烧瓶,加入50ml二氯甲烷后,搅拌10-20min,待充分溶解后加入3.0mmol甘草次酸,搅拌10min,冰浴至4℃,缓慢滴加EDCI的二氯甲烷溶液,滴加完毕继续保持4℃约30min后,室温反应24h。反应完毕后,依次用饱和碳酸氢钠溶液、饱和食盐水各洗两遍,无水硫酸钠干燥,回收溶剂,所得固体上柱层析(二氯甲烷∶甲醇=200∶1)分离,得到白色粉末1.058g,产率为53.4%。
1H-NMR(400MHz,CDCl3)(ppm):0.84,0.93,0.96,1.14,1.20,1.24,1.39(s,each,3H,7×-CH3),3.86(s,3H,-OCH3),3.88(s,3H,-OCH3),4.66(m,1H),5.72(s,1H,=CH-),6.47(d,J=16.2Hz,1H,-CH=),6.93(dd,J=8.0,1.2Hz,1H,Ar-H),7.05(t,J=8.0Hz,1H,Ar-H),7.17(dd,J=8.0,1.2Hz,1H,Ar-H),8.00(d,J=16.0Hz,1H,-CH=),1.00-3.00(22H,methyl-and methylene-of triterpenoid structure).13C-NMR(100MHz,CDCl3)(ppm):16.6,17.0,17.6,18.9,23.6,23.9,26.6,26.7,28.3,28.6,28.7,31.1,32.0,32.9,37.2,37.9,38.5,39.0,41.1,43.4,43.9,45.7,48.4,55.3,56.1(-OCH3),61.5(-OCH3),61.9,80.8,114.0,119.4,120.2,124.3,128.7,128.9,139.2,148.6,153.3,167.1,169.5,181.3(-COOH),200.5(-C=O).MS(ESI)m/z:659[M-H]-,calcd.for C41H56O7660.
实施例7
(2,5-dimethoxy)cinnamoyl-3β-Hydroxy-11-oxoolean-12-en-30-oic acid(7a)
将6.0mmol 2,5-二甲氧基桂皮酸、0.6mmolDMAP置于100ml圆底烧瓶,加入50ml二氯甲烷后,搅拌10-20min,待充分溶解后加入3.0mmol甘草次酸,搅拌10min,冰浴至4℃,缓慢滴加EDCI的二氯甲烷溶液,滴加完毕继续保持4℃约30min后,室温反应24h。反应完毕后,依次用饱和碳酸氢钠溶液、饱和食盐水各洗两遍,无水硫酸钠干燥,回收溶剂,所得固体上柱层析(二氯甲烷∶甲醇=200∶1)分离,得到白色粉末1.132g,产率为57.1%。
1H-NMR(400MHz,CDCl3)(ppm):0.85,0.94,0.98,1.16,1.21,1.25,1.40(s,each,3H,7×-CH3),3.80(s,3H,-OCH3),3.85(s,3H,-OCH3),4.68(m,1H),5.72(s,1H,=CH-),6.49(d,J=16.1Hz,1H,-CH=),6.90(m,1H,Ar-H),6.85(brs,1H,Ar-H),7.06(m,1H,Ar-H),7.96(d,J=16.1Hz,1H,-CH=),1.00-3.00(22H,methyl-and methylene-of triterpenoidstructure).13C-NMR(100MHz,CDCl3)(ppm):16.6,17.0,17.6,18.9,23.5,23.9,26.6,26.7,28.3,28.6,28.7,31.1,32.1,32.9,37.2,37.9,38.5,39.0,41.1,43.4,43.9,45.7,48.4,55.3,56.0(-OCH3),56.3(-OCH3),61.9,80.7,112.7,113.6,117.2,119.6,124.4,128.7,139.7,153.0,153.7,167.3,169.4,181.0(-COOH),200.4(-C=O).MS(ESI)m/z:659[M-H]-,calcd.for C41H56O7660.
实施例8
(2,3,4-trimethoxy)cinnamoyl-3β-Hydroxy-11-oxoolean-12-en-30-oic acid(8a)
将6.0mmol 2,3,4-三甲氧基桂皮酸、0.6mmolDMAP置于100ml圆底烧瓶,加入50ml二氯甲烷后,搅拌10-20min,待充分溶解后加入3.0mmol甘草次酸,搅拌10min,冰浴至4℃,缓慢滴加EDCI的二氯甲烷溶液,滴加完毕继续保持4℃约30min后,室温反应24h。反应完毕后,依次用饱和碳酸氢钠溶液、饱和食盐水各洗两遍,无水硫酸钠干燥,回收溶剂,所得固体上柱层析(二氯甲烷∶甲醇=200∶1)分离,得到白色粉末1.381g,产率为66.7%。
1H-NMR(400MHz,CDCl3)(ppm):0.84,0.93,0.96,1.15,1.20,1.24,1.39(s,each,3H,7×-CH3),3.87(s,3H,-OCH3),3.89(s,3H,-OCH3),3.92(s,3H,-OCH3),4.66(m,1H),5.72(s,1H,=CH-),6.40(d,J=16.0Hz,1H,-CH=),6.69(d,J=8.8Hz,1H,Ar-H),7.28(d,J=8.8Hz,1H,Ar-H),7.88(d,J=16.0Hz,1H,-CH=),1.00-3.00(22H,methyl-and methylene-of triterpenoid structure).13C-NMR(100MHz,CDCl3)(ppm):16.6,17.0,17.6,18.9,23.5,23.9,26.6,26.728.3,28.6,28.7,31.1,32.0,32.9,37.2,37.9,38.5,39.0,41.1,43.4,44.0,45.7,48.4,55.3,56.2(-OCH3),61.0(-OCH3),61.6(-OCH3),61.9,80.6,107.8,117.8,121.8,123.2,128.7,139.4,142.6,153.4,155.6,167.5,169.4,181.5(-COOH),200.4(-C=O).MS(ESI)m/z:689[M-H]-,calcd.for C42H58O8690.
实施例9
(3,4,5-trimethoxy)cinnamoyl-3β-Hydroxy-11-oxoolean-12-en-30-oic acid(9a)
将6.0mmol 3,4,5-三甲氧基桂皮酸、0.6mmolDMAP置于100ml圆底烧瓶,加入50ml二氯甲烷后,搅拌10-20min,待充分溶解后加入3.0mmol甘草次酸,搅拌10min,冰浴至4℃,缓慢滴加EDCI的二氯甲烷溶液,滴加完毕继续保持4℃约30min后,室温反应24h。反应完毕后,依次用饱和碳酸氢钠溶液、饱和食盐水各洗两遍,无水硫酸钠干燥,回收溶剂,所得固体上柱层析(二氯甲烷∶甲醇=200∶1)分离,得到白色粉末1.143g,产率为55.2%。
1H-NMR(400MHz,CDCl3)(ppm):0.84,0.93,0.97,1.15,1.20,1.24,1.39(s,each,3H,7×-CH3),3.88(s,3H,-OCH3),3.89(s,6H,2×-OCH3),4.68(m,1H),5.72(s,1H,=CH-),6.35(d,J=16.0Hz,1H,-CH=),6.75(s,2H,Ar-H),7.58(d,J=16.0Hz,1H,-CH=),1.00-3.00(22H,methyl-and methylene-of triterpenoid structure).13C-NMR(100MHz,CDCl3)(ppm):16.6,17.0,17.5,18.8,23.5,23.9,26.5,26.6,28.3,28.6,28.7,31.1,32.0,32.9,37.1,37.9,38.5,39.0,41.0,43.4,43.9,45.6,48.4,55.2,56.3(-OCH3),61.1(-OCH3),61.9,80.8,105.3,118.2,128.6,130.2,140.1,144.5,153.6,167.0,169.7,181.5(-COOH),200.5(-C=O).MS(ESI)m/z:689[M-H]-,calcd.for C42H58O8690.
实施例10
Phenylpropanoyl-3β-Hydroxy-11-oxoolean-12-en-30-oic acid(1b)
将2.0mmol化合物1a(实施例1制得)置于100ml圆底烧瓶,加入30ml THF后,搅拌10-20min,加入湿润的钯碳约50.0mg,H2环境,室温反应2h。反应完毕后,过滤除去钯碳(回收),回收THF,乙酸乙酯溶解过滤,滤液回收溶剂得白色粉末1.133g,产率为94.0%。
1H-NMR(400MHz,CDCl3)(ppm):0.80,0.84,0.84,1.13,1.15,1.23,1.27(s,each,3H,7×-CH3),2.64(m,2H,-CH2),2.96(m,2H,-CH2),4.52(m,1H),5.71(s,1H,=CH-),7.17-7.22(m,3H,Ar-H),7.27-7.30(m,2H,Ar-H),1.00-3.00(22H,methyl-and methylene-oftriterpenoid structure).13C-NMR(100MHz,CDCl3)(ppm):16.5,16.7,17.5,18.8,23.5,23.7,26.6,26.6,28.1,28.6,28.7,31.1,31.3,32.0,32.9,36.4,37.1,37.9,38.2,38.9,41.0,43.4,43.9,45.6,48.4,55.2,61.9,80.9,126.4,128.4,128.6,140.7,169.6,172.9,181.7(-COOH),200.5(-C=O).MS(ESI)m/z:601[M-H]-,calcd.for C39H54O5602.
实施例11
(2,3-dimethoxy)phenylpropanoyl-3β-Hydroxy-11-oxoolean-12-en-30-oicacid(2b)
将2.0mmol化合物6a(实施例6制得)置于100ml圆底烧瓶,加入30ml THF后,搅拌10-20min,加入湿润的钯碳约50.0mg,H2环境,室温反应2h。反应完毕后,过滤除去钯碳(回收),回收THF,乙酸乙酯溶解过滤,滤液回收溶剂得白色粉末1.289g,产率为97.3%。
1H-NMR(400MHz,CDCl3)(ppm):0.83,0.83,0.85,1.13,1.15,1.23,1.37(s,each,3H,7×-CH3),2.59-2.64(m,2H,-CH2),2.93-2.98(m,2H,-CH2),3.84(s,3H,-OCH3),3.85(s,3H,-OCH3),4.51(m,1H),5.71(s,1H,=CH-),6.80-6.77(m,2H,Ar-H),6.97(t,J=8.0Hz,1H,Ar-H),1.00-3.00(22H,methyl-and methylene-of triterpenoid structure).13C-NMR(100MHz,CDCl3)(ppm):16.5,16.8,17.5,18.8,23.5,23.7,25.7,26.6,26.6,28.2,28.6,28.7,31.1,32.0,32.9,35.4,37.1,37.9,38.2,39.0,41.0,43.4,43.9,45.6,48.4,55.2,55.9(-OCH3),60.7(-OCH3),61.8,80.7,110.9,121.9,124.0,128.6,134.5,147.4,152.9,169.6,173.1,181.5(-COOH),200.5(-C=O).MS(ESI)m/z:661[M-H]-,calcd.forC41H58O7662
实施例12
(2,3,4-trimethoxy)phenylpropanoyl-3β-Hydroxy-11-oxoolean-12-en-30-oicacid(3b)
将2.0mmol化合物8a(实施例8制得)置于圆底烧瓶,加入30ml THF后,搅拌10-20min,加入湿润的钯碳约50.0mg,H2环境,室温反应2h。反应完毕后,过滤除去钯碳(回收),回收THF,乙酸乙酯溶解过滤,滤液回收溶剂得白色粉末1.296g,产率为95.5%。
1H-NMR(400MHz,CDCl3)(ppm):0.81,0.83,0.84,1.12,1.15,1.22,1.37(s,each,3H,7×-CH3),2.58(t,J=8.0Hz,2H,-CH2),2.88(t,J=8.0Hz,2H,-CH2),3.83(s,3H,-OCH3),3.85(s,3H,-OCH3),3.89(s,3H,-OCH3),4.50(m,1H),5.71(s,1H,=CH-),6.57(d,J=8.8Hz,1H,Ar-H),6.83(d,J=8.8Hz,1H,Ar-H),1.00-3.00(22H,methyl-and methylene-oftriterpenoid structure).13C-NMR(100MHz,CDCl3)(ppm):16.5,16.8,17.5,18.8,23.5,23.7,25.7,26.5,26.6,28.1,28.6,28.7,31.0,32.0,32.8,35.6,37.0,37.8,38.2,38.9,41.0,43.3,43.9,45.6,48.4,55.1,56.1(-OCH3),60.8(-OCH3),61.0(-OCH3),61.8,80.6,107.2,123.9,126.6,128.5,142.4,152.0,152.5,169.6,173.2,182.0(-COOH),200.5(-C=O).MS(ESI)m/z:691[M-H]-,calcd.for C42H60O8692.
实施例13
(3,4,5-trimethoxy)phenylpropanoyl-3β-Hydroxy-11-oxoolean-12-en-30-oicacid(4b)
将2.0mmol化合物9a(实施例9制得)置于100ml圆底烧瓶,加入30ml THF后,搅拌10-20min,加入湿润的钯碳约50.0mg,H2环境,室温反应2h。反应完毕后,过滤除去钯碳(回收),回收THF,乙酸乙酯溶解过滤,滤液回收溶剂得白色粉末1.323g,产率为95.5%。
1H-NMR(400MHz,CDCl3)(ppm):0.79,0.83,0.85,1.12,1.15,1.23,1.37(s,each,3H,7×-CH3),2.63(t,J=8.0Hz,2H,-CH2),2.90(t,J=8.0Hz,2H,-CH2),3.81(s,3H,-OCH3),3.84(s,6H,2×-OCH3),4.53(m,1H),5.71(s,1H,=CH-),6.42(s,2H,Ar-H),1.00-3.00(22H,methyl-and methylene-of triterpenoid structure).13C-NMR(100MHz,CDCl3)(ppm):16.5,16.9,17.5,18.8,23.5,23.8,26.5,26.6,28.1,28.6,28.7,31.1,31.6,32.0,32.8,36.5,37.1,37.9,38.2,38.9,41.0,43.4,43.9,45.6,48.4,55.2,56.2(-OCH3),61.0(-OCH3),61.8,80.9,105.4,128.6,136.5,136.6,153.3,169.6,172.8,181.6(-COOH),200.5(-C=O).MS(ESI)m/z:691[M-H]-,calcd.for C42H60O8692.
实施例14
取实施例1~13任一制备的化合物10g,加入注射剂(包括冻干粉针剂和无菌分装干粉针剂)适当辅料,按注射剂(包括冻干粉针剂和无菌分装干粉针剂)工艺制备成抗肿瘤药注射剂。
实施例15
取取实施例1~13任一制备的化合物10g,加入片剂(包括缓控释片、骨架片、包衣片、分散片等)适当辅料,按片剂(包括缓控释片、骨架片、包衣片、分散片等)工艺制备成抗肿瘤药片剂。
实施例16
取取实施例1~13任一制备的化合物10g,加入胶囊剂适当辅料,按胶囊剂工艺制备成抗肿瘤药胶囊剂。
实施例17
取取实施例1~13任一制备的化合物10g,加入乳剂(包括微乳、纳米乳等)适当辅料,按乳剂(包括微乳、纳米乳等)工艺制备成抗肿瘤药乳剂。
实施例18
取取实施例1~13任一制备的化合物10g,加入颗粒剂适当辅料,按颗粒剂工艺制备成抗肿瘤药颗粒剂。
实施例19
取取实施例1~13任一制备的化合物10g,加入缓释控释剂适当辅料,按缓释控释剂工艺制成抗肿瘤药缓释控释剂。
实施例20
取取实施例1~13任一制备的化合物10g,加入口服液适当辅料,按口服液工艺制备成抗肿瘤药口服液。
实施例21
取取实施例1~13任一制备的化合物10g,加入脂质体剂型适当辅料,按脂质体工艺制备成抗肿瘤药脂质体剂型。
Claims (8)
1.具有如下通式1的化合物GA-CA:
其中,R1选自-H或-OCH3的任意一种,R2选自-H或-OCH3的任意一种,R3选自-H、-CH3或-OCH3的任意一种,R4选自-H或-OCH3的任意一种。
上述衍生物结构1a-9a其特征如下:
2.具有如下通式2的化合物GA-CA:
其中,R1选自-H或-OCH3的任意一种,R2选自-H或-OCH3的任意一种,R3选自-H或-OCH3的任意一种,R4选自-H或-OCH3的任意一种。
上述衍生物结构1b-4b其特征如下:
3.具有抗肿瘤作用的化合物8a
4.如权利要求1或3所述的化合物的制备方法,其特征在于该方法为:
所述反应在二氯甲烷、乙酸乙酯、甲醇或它们各种比例的混合溶剂中进行;涉及缩合反应在20-40℃下进行,催化剂为4-二甲氨基吡啶(DMAP),缩合剂为1-乙基-3-(3-二甲胺丙基)碳二亚胺盐酸盐(EDCI)或1,3-二环己基碳二亚胺(DCC)。
5.如权利要求2所述的化合物的制备方法,其特征在于该方法为:
在权利要求的1所述的化合物1a、6a、8a、9a进行氢化反应,在四氢呋喃、甲醇、丙酮或它们各种比例的混合溶剂中进行;涉及催化剂为钯碳或氢氧化钯碳,反应在-20℃至50℃进行。
6.如权利要求1或2或3任一所述化合物在制备抗肿瘤药物中的应用。
7.如权利要求6所述应用,其特征在于,所述化合物在制备治疗肝癌、结肠癌、宫颈癌药物中的应用。
8.一种抗肿瘤的药物组合物,其特征在于,该组合物包含权利要求1或2或3的化合物和药学上可接受的载体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610395107.XA CN107474097A (zh) | 2016-06-07 | 2016-06-07 | 具有抗肿瘤作用甘草次酸‑肉桂酸衍生物(ga‑ca)的制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610395107.XA CN107474097A (zh) | 2016-06-07 | 2016-06-07 | 具有抗肿瘤作用甘草次酸‑肉桂酸衍生物(ga‑ca)的制备方法及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107474097A true CN107474097A (zh) | 2017-12-15 |
Family
ID=60594232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610395107.XA Pending CN107474097A (zh) | 2016-06-07 | 2016-06-07 | 具有抗肿瘤作用甘草次酸‑肉桂酸衍生物(ga‑ca)的制备方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107474097A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110551169A (zh) * | 2019-09-10 | 2019-12-10 | 陈昱西 | 甘草次酸类衍生物及其制备方法和用途 |
CN111704646A (zh) * | 2020-06-23 | 2020-09-25 | 中国药科大学 | 甾体类化合物及其制备方法和用途 |
CN112521302A (zh) * | 2019-09-17 | 2021-03-19 | 薪火炙药(北京)科技有限公司 | 具有神经保护作用的辣椒碱类化合物cp-x-y及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105315321A (zh) * | 2014-07-01 | 2016-02-10 | 雷海民 | 具有抗肿瘤作用的化合物及其制备方法和应用 |
CN105622704A (zh) * | 2014-10-29 | 2016-06-01 | 思路迪(北京)医药科技有限公司 | 抗肿瘤药物x-toa的制备方法及其应用 |
-
2016
- 2016-06-07 CN CN201610395107.XA patent/CN107474097A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105315321A (zh) * | 2014-07-01 | 2016-02-10 | 雷海民 | 具有抗肿瘤作用的化合物及其制备方法和应用 |
CN105622704A (zh) * | 2014-10-29 | 2016-06-01 | 思路迪(北京)医药科技有限公司 | 抗肿瘤药物x-toa的制备方法及其应用 |
Non-Patent Citations (4)
Title |
---|
DHARMENDRA KUMAR YADAV等: "Design, Synthesis and In Vitro Evaluation of 18β-Glycyrrhetinic Acid Derivatives for Anticancer Activity Against Human Breast Cancer Cell Line MCF-7", 《CURRENT MEDICINAL CHEMISTRY》 * |
DHARMENDRA KUMAR YADAV等: "QSAR and Docking Based Semi-synthesis and in vitro Evaluation of 18β-glycyrrhetinic Acid Derivatives Against Human Lung Cancer Cell Line A-549", 《MEDICINAL CHEMISTRY》 * |
LI-JUN WANG等: "Synthesis, biological evaluation and structure–activity relationships of glycyrrhetinic acid derivatives as novel anti-hepatitis B virus agents", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 * |
YANG LI等: "Synthesis and Anticancer Activities of Glycyrrhetinic Acid Derivatives", 《MOLECULES》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110551169A (zh) * | 2019-09-10 | 2019-12-10 | 陈昱西 | 甘草次酸类衍生物及其制备方法和用途 |
CN110551169B (zh) * | 2019-09-10 | 2022-07-15 | 陈昱西 | 甘草次酸类衍生物及其制备方法和用途 |
CN112521302A (zh) * | 2019-09-17 | 2021-03-19 | 薪火炙药(北京)科技有限公司 | 具有神经保护作用的辣椒碱类化合物cp-x-y及其应用 |
CN111704646A (zh) * | 2020-06-23 | 2020-09-25 | 中国药科大学 | 甾体类化合物及其制备方法和用途 |
CN111704646B (zh) * | 2020-06-23 | 2021-09-28 | 中国药科大学 | 甾体类化合物及其制备方法和用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102850369B (zh) | 一氧化氮供体型冬凌草甲素14位羟基修饰衍生物、其制备方法及用途 | |
CN106866572B (zh) | 一氧化氮供体型β‑榄香烯衍生物及其制备方法和用途 | |
CN105315321B (zh) | 具有抗肿瘤作用的化合物及其制备方法和应用 | |
CN110229168B (zh) | 11,20-二羰基济源冬凌草甲素及其l-氨基酸-14-酯三氟乙酸盐 | |
CN106750250B (zh) | 以氨基酸作为连接臂的聚乙二醇齐墩果酸衍生物及其制备方法和应用 | |
CN107474097A (zh) | 具有抗肿瘤作用甘草次酸‑肉桂酸衍生物(ga‑ca)的制备方法及其应用 | |
CN104151391B (zh) | 一种具有抗肿瘤作用的齐墩果酸衍生物及其制备方法和用途 | |
CN106243182B (zh) | 甘草次酸-硫化氢供体试剂衍生物及其合成方法和应用 | |
CN106478760A (zh) | 具有抗肿瘤作用的三帖类衍生物tba-x及其制备方法和应用 | |
CN111471080B (zh) | ocotillol型人参皂苷元A环并氨基噻唑环衍生物及制备方法 | |
CN107286220B (zh) | 1,2,4-三氮唑偶联的二氢杨梅素衍生物及其制备方法和应用 | |
CN105524076A (zh) | 偶氮鎓二醇盐一氧化氮供体型冬凌草甲素衍生物、制备方法及用途 | |
CN102391352B (zh) | 救必应酸氨基酸衍生物及其在制备抗肿瘤的药物中的应用 | |
CN109867708B (zh) | 具有抗肿瘤作用的甘草次酸系列衍生物(tnga-x)的制备方法和应用 | |
CN109867709B (zh) | 具有抗肿瘤作用的甘草次酸系列衍生物(toga-x)的制备方法和应用 | |
CN106946974B (zh) | 一类含吡唑杂环的熊果酰胺衍生物及其合成与应用 | |
CN103880915A (zh) | 一种环戊烷并多氢菲骨架化合物及其制备方法 | |
CN105949139A (zh) | 一种仲丁基二苯基四嗪甲酰胺化合物及制备和应用 | |
CN109206389B (zh) | 异土木香内酯衍生物,其药物组合物及其用途 | |
CN102964320A (zh) | 19-羧基穿心莲内酯衍生物、制备方法及其医药用途 | |
CN109503697B (zh) | 3-(l-苯丙氨酸)-五环三萜衍生物及其合成方法和应用 | |
CN108164476B (zh) | 间苯二腈类化合物、其应用以及包含该化合物的药物 | |
CN105147669A (zh) | 三棱双苯内酯和三棱双苯内酯b的衍生物在制备抗炎药物中的应用 | |
CN109517026B (zh) | L-苯丙氨酸修饰的山楂酸及其合成方法和应用 | |
CN114149392B (zh) | 莪术烯含氮衍生物及其制备和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171215 |
|
WD01 | Invention patent application deemed withdrawn after publication |